ORKA
The table below shows Oruka Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $29.14M | $28.99M | $24.09M | $19.93M | $25.69M | $18.67M |
| SG&A |
Oruka Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2023. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.29M |
| $5.12M |
| $4.34M |
| $5.16M |
| $3.76M |
| $2.82M |
| Operating income | -$36.43M | -$34.10M | -$28.43M | -$25.09M | -$29.45M | -$21.49M |
| Income tax | - | - | - | - | - | - |
| Net income | -$31.82M | -$30.28M | -$24.57M | -$21.00M | -$28.62M | -$22.24M |
| EPS (diluted) | - | - | -$0.46 | -$0.40 | -$1.46 | -$6.96 |